KROS
Keros Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
11.03
▲ 0.08 (0.73%)
MARKET · —
Price
Open
10.90
Prev close
10.95
Day high
11.09
Day low
10.81
Volume
153.22K
Market cap
$218.69M
P/E (TTM)
—
52W range
9.69 – 22.55
Trailing performance
Returnvs SPY
1W
+9.21%
+10.6%
1M
+8.78%
+5.0%
3M
-1.69%
-4.8%
6M
-31.91%
-43.0%
YTD
-45.83%
-58.1%
1Y
-22.49%
-42.5%
3Y
-66.88%
-141.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$218.69M
Enterprise value$-23.19M
Revenue (TTM)$15.01M
Gross profit$-58.34M
EBITDA$-96.87M
Net income$-83.16M
EPS (TTM)$-3.22
Free cash flow$-27.17M
Total cash$257.61M
Total debt$15.72M
Book value / share$13.23
Shares outstanding19.83M
Float17.81M
Short % of float5.72%
Dividend yield—
Beta (5Y)1.01
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.67
PEG ratio—
Price / sales—
Price / book0.83
EV / revenue-1.54
EV / EBITDA0.24
Gross margin0.00%
Operating margin-655.84%
Profit margin0.00%
Return on equity-17.16%
Return on assets-11.78%
Debt / equity5.99
Current ratio21.96
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $244.06M | $3.55M | $151.00K | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $87.01M | -$187.35M | -$152.99M | -$104.68M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $87.01M | -$187.35M | -$152.99M | -$104.68M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.24 | -1.45 | -16.8% |
| Mar 2026 | -0.92 | -1.21 | -31.5% |
| Dec 2025 | -0.45 | -0.86 | -90.4% |
| Sep 2025 | -0.92 | -0.18 | +80.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.79 | 5 | $14.76M | +3.5% |
| Next quarter | -1.75 | 6 | $618.75K | +60.7% |
| Current year | -5.14 | 6 | $16.37M | -93.3% |
| Next year | -6.61 | 6 | $12.64M | -22.8% |
Analyst targets & ownership
Mean target$19.83
High target$25.00
Low target$16.00
Implied upside79.81%
Analyst count6
ConsensusBUY
Strong buy / Buy0 / 4
Hold4
Sell / Strong sell0 / 0
Held by insiders3.96%
Held by institutions95.32%
Institutions holding191
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+112.72K
Net buying
Buy transactions
14
124.71K shares
Sell transactions
5
11.99K shares
Net transactions
+19
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
785.95K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | LERNER LORENA RAQUEL PH.D. Officer |
SELL | 3.57K | $36.72K | Direct |
| Aug 17, 26 | BIENAIME JEAN-JACQUES Director |
BUY | 1.00K | $10.27K | Direct |
| Jul 15, 26 | BIENAIME JEAN-JACQUES Director |
BUY | 1.00K | $10.61K | Direct |
| Jul 1, 26 | PRENER ANNE Director |
STOCK | 13.79K | $0 | Direct |
| Jun 15, 26 | BIENAIME JEAN-JACQUES Director |
BUY | 1.00K | $10.19K | Direct |
| Jun 11, 26 | NEWTON CHARLES W. Director |
SELL | 550 | $5.52K | Direct |
| Jun 4, 26 | KNOWLES JULIUS Director |
SELL | 2.63K | $28.17K | Direct |
| Jun 4, 26 | SETH ALPNA Director |
SELL | 2.63K | $28.14K | Direct |
| Jun 4, 26 | FARZAN NIMA Director |
SELL | 2.63K | $28.17K | Direct |
| Jun 3, 26 | BIENAIME JEAN-JACQUES Director |
STOCK | 7.14K | $0 | Direct |
| Jun 3, 26 | GRAY MARY ANN Director |
STOCK | 7.14K | $0 | Direct |
| Jun 3, 26 | SETH ALPNA Director |
STOCK | 7.14K | $0 | Direct |
| Jun 3, 26 | FARZAN NIMA Director |
STOCK | 7.14K | $0 | Direct |
| Jun 3, 26 | KNOWLES JULIUS Director |
STOCK | 7.14K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHO ESTHER |
General Counsel | 39.76K | Sale |
CHYUNG YUNG H. M.D. |
Officer | 44.00K | Stock Award(Grant) |
GORDON CARL L |
Director | 1.02M | Stock Award(Grant) |
KARIV TOMER |
Director and Beneficial Owner of more than 10% of a Class of Security | 4.64M | Stock Award(Grant) |
KNOWLES JULIUS |
Director | 263.24K | Sale |
LERNER LORENA RAQUEL PH.D. |
Officer | 27.56K | Sale |
NUSSBAUM RAN |
Director and Beneficial Owner of more than 10% of a Class of Security | 4.64M | Stock Award(Grant) |
REGNANTE KEITH C |
Chief Financial Officer | 39.26K | Sale |
ROVALDI CHRISTOPHER |
Chief Operating Officer | 60.00K | Stock Award(Grant) |
SEEHRA JASBIR |
Chief Executive Officer | 440.71K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
10.75
+2.64% from price
SMA 20
10.51
+4.97% from price
SMA 50
10.67
+3.38% from price
SMA 100
10.98
+0.48% from price
SMA 200
13.93
-20.81% from price
EMA 12
10.73
+2.80% from price
EMA 26
10.65
+3.53% from price
EMA 50
10.75
+2.58% from price
RSI (14)
55.0
Neutral
MACD (12,26,9)
0.08
Hist 0.07
ATR (14)
0.57
5.16% of price
Realised vol 30D
52.3%
Annualised
Bollinger upper
11.32
20, 2σ
Bollinger lower
9.69
20, 2σ
50 / 200 cross
Death
10.67 vs 13.93
Trend bias
Below 200
-20.81%
Risk profile
Beta vs SPY
1.05
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
52.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-54.6%
Peak to trough
Max drawdown 5Y
-86.5%
Peak to trough
ATR 14
0.57
5.16% of price
Beta (reported)
1.01
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.12
Call-heavy session
Put / call open interest
3.27
Positioning, not flow
Max pain
12.50
+13.3% from spot
ATM implied vol
164.3%
Nearest strike to spot
Skew (10% OTM)
-29.9%
Calls bid over puts
Call volume
115
Contracts, this expiry
Put volume
14
Contracts, this expiry
Heaviest call OI
10.00
21 contracts
Heaviest put OI
12.50
95 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?
Insider Monkey · 8d ago
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Zacks · 18d ago
Keros Therapeutics Reports Second Quarter 2026 Financial Results
GlobeNewswire · 19d ago
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
GlobeNewswire · 23d ago
Incyte (INCY) Q2 Earnings and Revenues Top Estimates
Zacks · 25d ago
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
Zacks · 57d ago
Keros Therapeutics Appoints Anne Prener to its Board of Directors
GlobeNewswire · 58d ago
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
GlobeNewswire · 82d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.